Sensorion SA (ALSEN) - Total Liabilities

Latest as of June 2025: €16.36 Million EUR ≈ $19.13 Million USD

Based on the latest financial reports, Sensorion SA (ALSEN) has total liabilities worth €16.36 Million EUR (≈ $19.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Sensorion SA (ALSEN) net asset momentum to track the company's year-over-year net asset growth rate.

Sensorion SA - Total Liabilities Trend (2011–2024)

This chart illustrates how Sensorion SA's total liabilities have evolved over time, based on quarterly financial data. See Sensorion SA (ALSEN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Sensorion SA Competitors by Total Liabilities

The table below lists competitors of Sensorion SA ranked by their total liabilities.

Company Country Total Liabilities
Site Centers Corp
NYSE:SITC
USA $65.97 Million
RADCOM Ltd
F:RAM
Germany €30.87 Million
Mechema Chemicals Int
TWO:4721
Taiwan NT$843.04 Million
Dollar Industries Limited
NSE:DOLLAR
India Rs5.90 Billion
Atlan Holdings Bhd
KLSE:7048
Malaysia RM368.32 Million
PBA Holdings Bhd
KLSE:5041
Malaysia RM1.05 Billion
Aurora Cannabis Inc
NASDAQ:ACB
USA $207.47 Million
Gia Lai Electricity JSC
VN:GEG
Vietnam ₫8.69 Trillion

Liability Composition Analysis (2011–2024)

This chart breaks down Sensorion SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sensorion SA (ALSEN) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.90 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sensorion SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sensorion SA (2011–2024)

The table below shows the annual total liabilities of Sensorion SA from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 €17.14 Million
≈ $20.04 Million
+29.57%
2023-12-31 €13.23 Million
≈ $15.46 Million
-22.47%
2022-12-31 €17.06 Million
≈ $19.94 Million
+13.47%
2021-12-31 €15.03 Million
≈ $17.58 Million
+57.85%
2020-12-31 €9.52 Million
≈ $11.13 Million
-61.72%
2019-12-31 €24.88 Million
≈ $29.09 Million
+317.68%
2018-12-31 €5.96 Million
≈ $6.96 Million
+55.06%
2017-12-31 €3.84 Million
≈ $4.49 Million
+17.86%
2016-12-31 €3.26 Million
≈ $3.81 Million
-11.91%
2015-12-31 €3.70 Million
≈ $4.33 Million
+47.11%
2014-12-31 €2.52 Million
≈ $2.94 Million
+7.83%
2013-12-31 €2.33 Million
≈ $2.73 Million
+561.52%
2012-12-31 €352.61K
≈ $412.24K
+67.50%
2011-12-31 €210.51K
≈ $246.11K
--

About Sensorion SA

PA:ALSEN France Biotechnology
Market Cap
$173.58 Million
€148.47 Million EUR
Market Cap Rank
#17249 Global
#255 in France
Share Price
€0.29
Change (1 day)
+3.78%
52-Week Range
€0.23 - €0.70
All Time High
€12.53
About

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more